Valued at approximately US$ 20 Billion in 2022, the global fatty liver treatment market is expected to develop at a CAGR of 5% over the next 10 years. In 2032, analysts anticipate the fatty liver treatment market size would be worth around US$ 32.5 Billion.
Fatty Liver Treatment Market Size Value (2022)
US$ 20 Billion
Fatty Liver Treatment Market Size Value (2032)
US$ 32.5 Billion
Fatty Liver Treatment Market Growth Rate (2022-2032)
Sedentary lifestyles, obesity, excessive alcohol intake, and a lack of physical activity are the main causes of fatty liver production. As a result, the market is projected to see an increase in demand for fatty liver treatments for these conditions. However, till 2027, the market expansion for the treatment of fatty liver illnesses may be hampered by strict government requirements for the licensing of fatty liver medications and significant side effects linked with the drugs used during the treatment.
The largest opportunity for the market for treating fatty liver disorders is presented by emerging economies in the Asia-Pacific and Latin America with their rising health expenditures. While, North America with a higher proportion of the geriatric population still holds the biggest market share due to the region's high concentration of important product manufacturers, rising R&D spending, and high concentration of major manufacturers.
Due to an increase in new research and advancements in the market for treating fatty liver illnesses, China and India are anticipated to rise exponentially during the forecast years. Additionally, untapped emerging markets in other geographical regions are anticipated to present higher opportunities for fatty liver treatment market growth due to advancements in healthcare infrastructure, a surge in unmet medical demands, and a rise in international funding.
According to the kind of therapy, the antiviral medicine segment led the overall market until the year 2021 and is predicted to do so again throughout the forecast period since viral liver disorders are becoming more common. As per the fatty liver treatment market analysis report, Thiazolidinedione was the drug type segment with the highest growth during the previous years, and it is anticipated that this trend would persist over the projection period as well.
The global market for pharmaceuticals used to treat fatty liver disease is expected to experience substantial expansion as a result of recent research and advancements aimed at developing effective and affordable therapies. Nowadays, the fatty liver treatment market players are concentrating more on creating cost-effective treatments for mass manufacturing on a worldwide scale. Additionally, there is a growing possibility for major firms to engage in the fatty liver disease treatment market due to numerous technical developments in medication or drug delivery methods.
Fatty liver disease is the most common liver dysfunction in which the triglyceride fat accumulates in liver cells. The fatty liver disease is caused due to obesity and excessive alcohol intake. Fatty liver is caused due to excessive alcohol intake known as Alcoholic Fatty Liver Disease (ALD) and obesity or insulin resistance known as Non-Alcoholic Liver Disease (NAFLD).
The major risk factors associated with fatty liver disease are alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, progressive liver fibrosis and hepatocellular carcinoma (HCC) as well as increased cardiovascular disorder. Fatty liver disease is currently expected to be the leading cause of hepatocellular carcinoma.
The technological advancements and the routine liver function tests are now resulting in the early detection of fatty liver treatment. The increase in incidence of fatty liver disease associated with excessive alcohol intake is expected to create an opportunity for the growth of fatty liver treatment market during the forecast period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The incidence rate of fatty liver disease particularly the Non-Alcoholic Liver Disease (NAFLD) was estimated to increase approximately by 20 to 25% in 2015. Thus, the market for fatty liver treatment is anticipated to grow significantly during the forecast period.
The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to fuel growth of global fatty liver treatment market. However, the side effects associated with the treatment, and increasing stringency in the regulatory requirements are some of the major factors limiting the growth of global fatty liver treatment market.
Due to the availability of variety of agents for fatty liver treatment, the market for overall fatty liver treatment is expected to grow significantly. Additionally, the investment of pharmaceutical companies in the research and development are anticipated to contribute in the growth of fatty liver treatment market.
In U.S. it is estimated that more than 15 Mn people are involved in the abuse or over abuse of alcohol and among them more than 90% people suffer from fatty liver disease. Thiazolidinedione and metformin are widely used for the Non-Alcoholic Liver Disease (NAFLD) caused due to insulin resistance.
Thus, thiazolidinedione and metformin are expected to highly contribute in the growth of global fatty liver treatment market.
Geographically, the global fatty liver treatment market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa. North America and Europe are expected to dominate the fatty liver treatment market due to abuse cases of alcoholic beverages.
APAC is the fastest growing market with increasing prevalence of fatty liver disease associated with factors such as growing alcoholic intake, drug abuse and high prevalence of diabetes. The global fatty liver treatment market is expected to grow remarkably during the forecast period due to increasinginvestment by multinational companies in the research and development.
Some of the key players operating in this market are Cardax, Inc., Daewoong Co., Ltd., Hoffmann-La Roche Ltd., Glenmark. GW Pharmaceuticals, Limerick BioPharma, Inc., Merck & Co., Inc., Novartis AG, Orchid Chemicals & Pharmaceuticals Ltd, AstraZeneca.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The global fatty liver treatment market has been classified on the basis of drugs, end use and geography.